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Methods: Cell subtypes underwent immunophenotyping using specific monoclonal antibodies (anti-CD3 CY5, anti-CD4 FITC, anti-CD25, anti-Foxp3, anti-CD19 PE) and flow cytometry. 
Results

Introduction
Systemic lupus erythematosus (SLE) is a multiorganic disease characterized by immune dysregulation; loss of tolerance to self-antigens leads to formation of immune complexes. 1 Recent data in both human SLE and mouse models have highlighted the role of type I interferon's (α/β) in the initiation and perpetuation of the disease. 2 Individuals with SLE are more susceptible to thrombosis than the general population, and the antiphospholipid syndrome (APS) is a well-known risk factor for vascular obstruction in such patients. 3 The reason why patients with SLE and APS produce pathogenic antiphospholipid (aPL) antibodies has been a matter of intense debate. CD4 + CD25 + Foxp3 + regulatory T (Treg) cells are a distinct thymically derived or inducible subset of T cells with unique immunosuppressive abilities. Quantitative or functional impairment of Treg lymphocytes seems to direct the immune system toward autoimmunity. 4 It is frequently observed an imbalance between IL-17 producing T helper (Th17) and Treg cells during the course of SLE, with marked impairment of the Treg subset. 5 It is noteworthy that the blockage of Treg cells by interferon-α-producing antigen presenting cells may contribute to loss of peripheral tolerance in SLE. 6 A CD4
+ Treg cell dysfunction has been documented in a number of autoimmune disorders. 7 In SLE cases, most studies have shown decreased number of circulating Tregs in active disease, but data are still conflicting. 8 B lymphocytes, in turn, are pivotal cells in SLE; they are linked to antigen-presentation, autoantibody synthesis and cytokine production. It is noteworthy that a distinct subset of B cells shown to exert immunosuppressive effects; 9 these IL-10-producers and regulatory-B cells, knowingly able to suppress T helper cells differentiation, appear to be functionally impaired in SLE patients. 10 Considering the importance of the interplay of T, Treg cells and B lymphocytes in the immunopathogenesis of SLE (5-7; 9,10) we set up to originally quantify total lymphocytes, Treg cells, CD3 + CD19 -T cells and CD3 -CD19 + B cells in a Brazilian survey of patients with SLE/ secondary APS (SLE/APS) and healthy controls.
Material and methods
This cross-sectional study included patients with SLE and history of secondary APS from our Outpatient Lupus Clinic. Clinical and laboratory diagnosis of SLE were based on the American College of Rheumatology 1997 criteria, 11 while the Sidney 2006 criteria was utilized to diagnose APS. 12 Lupus activity was assessed by the systemic lupus erythematosus disease activity index, SLEDAI. 13 The exclusion criteria were as follows: 1) age below 16 years; 2) infective endocarditis or other current infections; 3) diabetes mellitus; 4) neoplasms (current or past); and 5) infection by human immunodeficiency virus or Treponema pallidum. The control group comprised healthy individuals aged more than 16 years-old, matched by age and sex, and with no APS, connective tissue disorders, neoplasms or current infections. Clinical and demographic data were obtained from a chart review and interview with patients or family after informed consent. The study was approved by the local ethics committee.
Cell subtypes underwent immunophenotyping using the specific monoclonal antibodies anti-CD3CY5, anti-CD4 FITC, anti-CD25, anti-Foxp3 and anti-CD19 PE (Biosciences, San Jose, CA, USA) and identified by multicolor flow cytometry.
14 Quantitative statistical analysis was performed using SPSS 17.0 software (SPSS Inc, Chicago, IL, USA). The significance level was set at a = 0.05 (two-tailed). The results were shown as means and standard deviation or by absolute and relative frequencies. The statistical analysis was performed by Student's t test and the Mann-Whitney test for the continuous variables, and chi-square or Fisher's exact test for categorical variables. The Pearson test was utilized to correlate circulating cell subtypes with the SLEDAI. An analysis of covariance (ANCOVA) was performed to evaluate relationships between variables.
Results
Twenty-five patients with SLE/APS and 25 healthy controls entered the study. Middle-aged (mean age 43.5 years) females (96%) highly predominated in our SLE/APS survey. Twenty-four patients (96%) were caucasians. Mean duration of the disease was 9.87 years, and the average SLEDAI score was 10 ± 5.77. At the moment of evaluation, arthritis (36%), oral ulcers (32%), malar rash (24%), seizures (16%), nephritis (12%), and leukopenia (8%) were the most frequent SLE manifestations. All patients had antinuclear antibodies, and 40% were positive for anti-dsDNA. Low complement levels were seen in 8% of patients.
Regarding the APS clinical features, deep vein thrombosis (DVT) was seen in 15 patients (60%), while fetal losses (so considered after 12 weeks of pregnancy) occurred in 6 patients (24%). Optic neuritis was seen in 4 cases (16%). Stroke and miscarriages were each diagnosed in 3 cases (12%). Moderate or high levels of anticardiolipin (aCL) antibodies were detected in 21 patients (84%), whereas lupus anticoagulant was present in 9 patients (36%). Fourteen patients (56%) were on oral anticoagulation regime with warfarin, and the remaining was being treated with low-dose aspirin.
Chloroquine, azathioprine and corticosteroids were being utilized by 9 patients (36%), 5 patients (20%) and 16 patients (64%), respectively. Fig. 2 . A significant negative correlation of both cell subtypes with the SLEDAI was obtained, indicating that a lower number of Treg and CD3 -CD19 + B cells were linked to increasing scores of lupus activity. Levels of circulating Treg cells did not signifi cantly vary among users or nonusers of chloroquine, azathioprine and corticosteroids (p = 0.90; p = 0.76 and p = 0.29 in the chi-square test, respectively). Similarly, the number of CD3 -CD19 + B cells did not signifi cantly differ in users on nonusers of these medicines (p = 0.462; p = 0.512 and p = 0.341 in the chi-square test, respectively).
When we compared cell subtypes selectively in 5 patients with inactive SLE/APS (SLEDAI < 4) and 25 healthy controls, only the CD3 -CD19 + B population remained diminished in the fi rst group (5.37 ± 1.95% × 9.25 ± 3.00%; p = 0.003; Student's t test).
Discussion
A number of reports have accounted for a decrease of Treg cells in patients with SLE. [15] [16] [17] As far as we are aware, this study is the fi rst to approach circulating Treg cells and B lymphocytes in Brazilian patients with SLE and secondary APS. Our survey included predominantly middle-aged white females with high SLEDAI, and mean disease duration of approximately a decade. Arthritis and oral ulcers were the prominent SLE fi ndings, while DVT and aCL antibodies were cardinal APS features.
We have found a decreased number of circulating CD3 -CD19 + B cells in our SLE/APS patients when compared to controls. It is important to say that there was no association of CD3 -CD19 + B cell count with intake of chloroquine, azathioprine and steroids. The reasons for this B cell decrease in SLE/ APS patients are nebulous, but an explanation could be autoantibodies directed to B lymphocytes or intrinsic defects of B cell subsets. The fact that B cell depletion was confi rmed even in the 5 patients with inactive SLE might support the latter.
We could only suppose the hypothesis that the population with B cells depletion is the IL-10 producer subset with immunosuppressive properties. It is noteworthy that competent B cells seem to be important to trigger Treg activity, as shown in patients with common variable immunodefi ciency 18 . Reduced numbers of circulating CD4 + CD25 + Foxp3 + Treg cells were seen in our SLE/APS patients as compared to controls. As occurred the with the B cell subtype, Treg cells depletion was confi rmed after controlling (ANCOVA) for total lymphocyte count. Decreasing levels of circulating Treg cells, just as seen with the CD3 -CD19 + B subset, were correlated with higher scores of disease activity. Diminished levels of Treg cells have been associated with active SLE 19, 20 , but other reports 21, 22 questioned this fi nding. In our study, Treg cells depletion could be representative of an intrinsic defect related to previous SLE/ APS, or current SLE activity. Patients with inactive SLE did not show Treg reduction, which favors the second hypothesis. It is worthy of note that there was no association between Treg cells decrease and the intake of chloroquine, azathioprine or steroids in our patients either. Our group recently reported low levels of circulating Treg and also of CD3 -CD19 + B cells in patients with primary APS 23 . These data, combined with the current study, imply that depletion of both subsets occurs in APS populations as a whole. If this assumption will be confirmed, the Treg cells decrease may comprise one of the immune mechanisms leading to pathogenic aPL responses in primary or secondary APS. Nevertheless, it should be considered that Treg cells decrease in our SLE/APS patients seemed to relate more to SLE activity than any other particular factor.
Recent data disclosed that any quantitative analysis of Tregs in patients with autoimmune disorders have to be seen with some caution. The reg cells show formidable plasticity and comprise a heterogeneous population of suppressive cells, non-functional Treg cells and IL-17A-producing Treg cells acting as effector T lymphocytes. Thus, the simple numeric count of Tregs might not be truly representative of their functional status. 24 Some other limitations of our study must be mentioned. Even though the majority of our patients showed active SLE, the APS thrombotic manifestations were not current; newer studies should investigate the biological function of Treg cells and B lymphocytes during the thrombotic event and also in a longitudinal analysis. Given the small sample, we could not subgroup patients by SLE/APS features or drug dosage. The small number of patients with inactive SLE restricted the statistical power of the article. The same way, the lack of comparison between patients with SLE and without APS limited our conclusions.
Up to date, the treatments of SLE and APS have been reasoned in immunosuppression and anticoagulation, respectively. A direct immunomodulatory approach shifting the balance to favor Treg cells is being tried with autologous Treg cell therapy in type-1 diabetes, 25 and such intervention might be promising for SLE and APS as well. Recently, it was noticed that Treg cells were able to prolong the interval of remission induced by conventional cytostatic drugs in (NZB × NZW) F1 lupus mice. 26 Although many questions concerning the pathogenesis of SLE and APS remain undefined, it is possible that the progression of the disease results from a breakdown in Treg-dependent peripheral self-tolerance. In this context, Treg-based immunotherapy might have a place in the maintenance of disease remission in this group of patients.
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